Stacey Bowlin Joins Georgia Bio as Senior Vice President of Industry Engagement and Marketing

Georgia Bio, the state’s life science trade association, announced today the appointment of Stacey Bowlin as the organization’s Senior Vice President of Industry Engagement and Marketing. Bowlin will collaborate closely with Georgia Bio’s CEO on the company's strategic priorities, including the company’s go-to-market positioning and its integrated work with members.

 

“Stacey is an association brand strategist who will help both our members and GA Bio harness change to maximize performance and connectivity with key stakeholders across the state. She’ll be invaluable in driving our company’s strategic initiatives forward as we continue to evolve and grow," said Georgia Bio CEO Maria Thacker Goethe. “We’re very pleased to welcome Stacey to the organization.”

 

Over the course of her career, Bowlin has worked for a range of service organizations delivering marketing and event solutions to drive growth, retention, and revenue. Most recently, Bowlin worked at California Life Sciences, where she served as the association's Senior Vice President of Marketing and Industry Engagement. At CLS, she built a marketing function that included the organization’s communications and profile building efforts, events portfolio, sponsorship and other non-dues revenue initiatives. Stacey also oversaw CLS’ entrepreneurship programs, with an emphasis on expanding opportunities for startup companies, including CLS’s acclaimed FAST advisory program, and new initiatives that support the innovation pipeline. 

 

Previously, she spent more than a decade at the Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. 

 

"I am excited to work with the GA Bio team to amplify their portfolio of programs, events, and initiatives, helping our members advance critical products and services that will transform patient’s lives,” said Stacey Bowlin. “Together, we will continue to focus on the needs of our members.”

 

Georgia Bio also recently welcomed Katie Rogers to the organization. In her role as Director of Innovation & Entrepreneurship, Katie will focus on entrepreneurship initiatives connecting life science startups to resources needed to help them scale their ventures. She will also serve as the liaison for many of Georgia Bio’s committees and networks to ensure strong partnerships.

 

About Georgia Bio


Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org | www.georgiabioed.org


MEDIA CONTACT:

Melissa Carter

404-920-2043

mcarter@gabio.org

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS